OraSure Technologies, Inc. (OSUR) Stock

OraSure Technologies, Inc. (OSUR) is a Healthcare stock trading at $3.75 (as of 2026-08-20), with a market capitalization of $258.63M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OraSure Technologies, Inc., through its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States and internationally. It operates in two segments—Diagnostics and Molecular Solutions—and offers tests such as OraQuick and InteliSwab, along with specimen collection devices for use with screening and confirmatory testing.

Understand OraSure Technologies, Inc.: how it makes money

OraSure Technologies develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices, selling diagnostics and molecular solutions to customers in the United States and internationally, including rapid test products and related collection and sample management solutions.

Even with a 42.3% gross margin, the company reports a -83.3% operating margin, so near-term profitability is determined more by operating cost levels (and operating leverage) than by product gross profit.

Revenue by segment (latest quarter)
Diagnostics	$0.0B
Molecular Solutions	$0.0B

Business quality (Weak): Data provided includes margins and a KPI set, but total revenue is shown as 0.0B while several KPI and segment revenue candidates are non-zero, so exact scaling of segments to total revenue may be limited by rounding or missing reconciliation.

Bull case

Non-COVID Revenue is present in the provided KPI set, suggesting an ongoing base business beyond the specific COVID-19 products: Non-COVID Revenue is labeled at 0.05B.
Production and demand indicators for IntelliSwab are tracked via installed capacity and unit consumption: IntelliSwab Units Consumed is labeled at 10,000,000 count, and IntelliSwab Installed Capacity for Tests Per Year is labeled at 55,000,000 (with an Expanded value of 70,000,000).
The company indicates continued availability under a federal government contract for additional tests: Remaining IntelliSwab Tests Under Federal Government Contract (Additional) is labeled at 64,000,000 count.

Bear case

Operating profitability is weak relative to gross profitability: Gross margin is 42.3% while operating margin is -83.3%.
Core molecular revenue is shrinking year over year in the provided KPI set: Molecular Products and Services Revenue Decline (Year Over Year) is labeled at 48%.
COVID-19 product contribution appears to be absent in the provided KPI set for this period: COVID-19 Products Revenue is labeled at 0.0B.

Valuation — source: SEC EDGAR (first-party)
Price	$3.75
Market Cap	$258.63M
Price / Book	0.81
Price / Sales	2.28
FCF Yield	-38.7%
DCF Value (model)	$7.74
DCF Upside vs Price	106.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$115.02M
Net Margin	-59.8%
Revenue Growth (YoY)	-38.1%
EPS Growth (YoY)	261.5%
FCF Growth (YoY)	-325.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.25 (grey)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($19.55M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Carrie Eglinton Manner
Employees	501
Country	US
IPO Date	1986-11-17

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.